News
Patients who are prescribed Wegovy or Ozempic can now use GoodRx to access the medications at just $499 a month if they skip ...
The company hopes an important CVS deal and broader legal action against the makers of knockoff Wegovy can solidify its ...
Here are some of the biggest premarket U.S. stock movers today: Palo Alto Networks (NASDAQ: PANW) stock rose 0.4%, with the ...
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
Zacks.com on MSN4h
NVO Stock Up on FDA Nod for Wegovy in MASH: More Upside Ahead?
Novo Nordisk surges as Wegovy secures FDA approval for MASH, marking a breakthrough in liver care and expanding its blockbuster reach.
Longer-term studies will be needed to track whether per-patient costs might drop over time with continued use of the meds.
Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.
Eli Lilly told the firm it is not interested in exclusive "one-of-one" deals with PBMs, while Novo Nordisk said CVS approached the drugmaker about the Wegovy agreement, according to Seigerman.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback